Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades

Anaerobe

Volumn 31, Issue , 2015, Pages 4-10

  Boyanova, Lyudmila ^a   Kolarov, Rossen ^b   Mitov, Ivan ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

ADM; Anaerobes; Anaerobic; Antibiotic; BMM; CA SFM; CLSI; ET; EUCAST; Factors; Increase; Resistance; SGE

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN; CHLORAMPHENICOL; CLINDAMYCIN; ERTAPENEM; FUSIDIC ACID; IMIPENEM; LINCOSAMIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TROVAFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; CAMPYLOBACTER; FUSOBACTERIUM; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PARABACTEROIDES; PEPTOCLOSTRIDIUM DIFFICILE; PORPHYROMONAS; PREVOTELLA; PREVOTELLA INTERMEDIA; PREVOTELLA NIGRESCENS; REVIEW; TREND STUDY; BACTERIAL INFECTIONS; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; UNITED STATES;

CLOSTRIDIUM DIFFICILE; PREVOTELLA;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; UNITED STATES;

EID: 84922741794     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.05.004     Document Type: Review

References (37)

1. Goldstein E.J., Citron D.M., Goldman P.J., Goldman R.J. National hospital survey of anaerobic culture and susceptibility methods: III. Anaerobe 2008, 14:68-72.
2. Goldstein E.J.C., Citron D.M. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I. Clin Microbiol Newsl 2011, 33:1-8.
3. Smith A.J., Lockhart D.E., Tyers A., Poxton I.R. Asurvey of the identification and susceptibility testing of anaerobes in diagnostic microbiology laboratories in Scotland, UK. JAntimicrob Chemother 2010, 65:805.
4. Rautemaa-Richardson R., der Reijden Wa W.A., Dahlen G., Smith A.J. Quality control for diagnostic oral microbiology laboratories in European countries. JOral Microbiol 2011, 3.
5. Brook I., Wexler H.M., Goldstein E.J. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013, 26:526-546.
6. Boyanova L., Kolarov R., Gergova G., Deliverska E., Madjarov J., Marinov M., et al. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria. JMed Microbiol 2006, 55:1285-1289.
7. Betriu C., Culebras E., Gómez M., López F., Rodríguez-Avial I., Picazo J.J. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain. Antimicrob Agents Chemother 2008, 52:2686-2690.
8. Dubreuil L., Odou M.F. Anaerobic bacteria and antibiotics: what kind of unexpected resistance could I find in my laboratory tomorrow?. Anaerobe 2010, 16:555-559.
9. Boyanova L., Kolarov R., Gergova G., Dimitrova L., Mitov I. Trends in antibiotic resistance in Prevotella species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003-2009. Anaerobe 2010, 16:489-492.
10. Liu C.Y., Huang Y.T., Liao C.H., Yen L.C., Lin H.Y., Hsueh P.R. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
11. Veloo A.C., Seme K., Raangs E., Rurenga P., Singadji Z., Wekema-Mulder G., et al. Antibiotic susceptibility profiles of oral pathogens. Int J Antimicrob Agents 2012, 40:450-454.
12. van Winkelhoff A.J., Herrera D., Oteo A., Sanz M. Antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in The Netherlands and Spain. JClin Periodontol 2005, 32:893-898.
13. Kulik E.M., Lenkeit K., Chenaux S., Meyer J. Antimicrobial susceptibility of periodontopathogenic bacteria. JAntimicrob Chemother 2008, 61:1087-1091.
14. Pierard D., De Meyer A., Rosseel P., Glupczynski Y., Struelens M.J., Delmee M., et al. Invitro activity of amoxycillin plus clavulanic acid and ticarcillin plus clavulanic acid compared with that of other antibiotics against anaerobic bacteria. Acta Clin Belg 1989, 44:228-236.
15. Pierard D., De Meyer A., Rosseel P., Van Cauwenbergh M., Struelens M.J., Delmee M., et al. Invitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey. Acta Clin Belg 1996, 51:70-79.
16. Wybo I., Van den Bossche D., Soetens O., Vekens E., Vandoorslaer K., Claeys G., et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. JAntimicrob Chemother 2014, 69:155-161.
17. Roh K.H., Kim S., Kim C.K., Yum J.H., Kim M.S., Yong D., et al. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea. Korean J Lab Med 2009, 29:293-298.
18. Karlowsky J.A., Walkty A.J., Adam H.J., Baxter M.R., Hoban D.J., Zhanel G.G. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012, 56:1247-1252.
19. Nagy E., Urbán E., Nord C.E. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011, 17:371-379. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria.
20. Jamal W., Shahin M., Rotimi V.O. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007. Anaerobe 2010, 16:1-5.
21. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Hecht D.W., Goldstein E.J., et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010, 50(Suppl.1):S26-S33.
22. Treviño M., Areses P., Peñalver M.D., Cortizo S., Pardo F., del Molino M.L., et al. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe 2012, 18:37-43.
23. Boyanova L., Osmanliev D., Petrov D., Mitov I., Usunova I., Petrov S., et al. Anaerobic cocci and their resistance patterns to penicillin, cefoxitin, clindamycin and metronidazole: a Bulgarian study. Clin Microbiol Infect 2000, 6:623-624.
24. Taori S.K., Hall V., Poxton I.R. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. JMed Microbiol 2010, 59:338-344.
25. Baines S.D., O'Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. JAntimicrob Chemother 2008, 62:1046-1052.
26. Ilchmann C., Zaiss N.H., Speicher A., Christner M., Ackermann G., Rohde H. Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in Clostridium difficile isolates from 1990 and 2008. Eur J Clin Microbiol Infect Dis 2010, 29:1571-1573.
27. Spigaglia P., Barbanti F., Dionisi A.M., Mastrantonio P. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. JClin Microbiol 2010, 48:2892-2896.
28. Norén T., Alriksson I., Akerlund T., Burman L.G., Unemo M. Invitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010, 16:1104-1110.
29. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Goldstein E.J., Harrell L., et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011, 17:147-151.
30. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
31. Eitel Z., Sóki J., Urbán E., Nagy E. The prevalence of antibiotic resistance genes in Bacteroides fragilis group strains isolated in different European countries. Anaerobe 2013, 21:43-49. ESCMID Study Group on Anaerobic Infection.
32. Hartmeyer G.N., Sóki J., Nagy E., Justesen U.S. Multidrug-resistant Bacteroides fragilis group on the rise in Europe?. JMed Microbiol 2012, 61:1784-1788.
33. Kirchner M., Mafura M., Hunt T., Card R., Anjum M.F. Antibiotic resistance gene profiling of faecal and oral anaerobes collected during an antibiotic challenge trial. Anaerobe 2013, 23:20-22.
34. Alauzet C., Mory F., Teyssier C., Hallage H., Carlier J.P., Grollier G., et al. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother 2010, 54:60-64.
35. Sherwood J.E., Fraser S., Citron D.M., Wexler H., Blakely G., Jobling K., et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011, 17:152-155.
36. Brook I. Antimicrobial treatment of anaerobic infections. Expert Opin Pharmacother 2011, 12:1691-1707.
37. Cheadle W., Lee J.T., Napolitano L.M., Nichols R.L. Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections. Surg Infect (Larchmt) 2010, 11:487-494.